# Evaluating the Bioequivalence of HIP1403, HGP0919

> **NCT02473900** · PHASE1 · COMPLETED · sponsor: **Hanmi Pharmaceutical Company Limited** · enrollment: 32 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** HIP1403
- **DRUG:** HGP0919

## Key facts

- **NCT ID:** NCT02473900
- **Lead sponsor:** Hanmi Pharmaceutical Company Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-04
- **Primary completion:** 2015-04
- **Final completion:** 2015-04
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2016-10-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02473900

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02473900, "Evaluating the Bioequivalence of HIP1403, HGP0919". Retrieved via AI Analytics 2026-09-03 from https://api.ai-analytics.org/clinical/NCT02473900. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*